| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11307-019-01351-4 |
| P698 | PubMed publication ID | 31016638 |
| P50 | author | Edith Motschall | Q28323618 |
| Poul Flemming Høilund-Carlsen | Q59223358 | ||
| Oke Gerke | Q39394836 | ||
| P2093 | author name string | Werner Vach | |
| Karen Ehlers | |||
| P2860 | cites work | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer | Q41049696 |
| (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. | Q41161118 | ||
| Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. | Q41378943 | ||
| The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy | Q41425861 | ||
| Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use? | Q41452455 | ||
| Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. | Q41546471 | ||
| Radiofrequency ablation of advanced lung tumors: imaging features, local control, and follow-up protocol | Q41573120 | ||
| Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer | Q41624801 | ||
| PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. | Q41666443 | ||
| Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. | Q42373344 | ||
| Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria | Q42924751 | ||
| The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation | Q43670431 | ||
| Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma | Q43852845 | ||
| 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. | Q44151994 | ||
| Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy | Q44238456 | ||
| Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib | Q44697111 | ||
| Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. | Q45020726 | ||
| Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography--a novel concept | Q45288088 | ||
| Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism | Q47398792 | ||
| PERCIST in Perspective. | Q47698249 | ||
| Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. | Q47925636 | ||
| To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan | Q48140753 | ||
| Uptake of Radium-223 Dichloride and Early [(18)F]NaF PET Response Are Driven by Baseline [(18)F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients | Q48194054 | ||
| Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). | Q48283622 | ||
| Correction for Partial Volume Effect Is a Must, Not a Luxury, to Fully Exploit the Potential of Quantitative PET Imaging in Clinical Oncology | Q48538174 | ||
| 18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors | Q48564640 | ||
| International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). | Q48669191 | ||
| Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type | Q49133025 | ||
| Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor | Q49149410 | ||
| 18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas. | Q50550439 | ||
| Evaluating tumor response of non-small cell lung cancer patients with ¹⁸F-fludeoxyglucose positron emission tomography: potential for treatment individualization. | Q50603799 | ||
| Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. | Q50985747 | ||
| ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. | Q51009203 | ||
| (18)F-FDG PET/MRI for therapy response assessment in sarcoma: comparison of PET and MR imaging results. | Q52864962 | ||
| [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy. | Q52984200 | ||
| Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma. | Q52984765 | ||
| Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results. | Q52988029 | ||
| RAPID Trial Demonstrates Low Positive Predictive Value of Interim FDG-PET in Early-stage Hodgkin Lymphoma After Three Cycles of ABVD. | Q52988308 | ||
| Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation. | Q52989514 | ||
| Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. | Q52990489 | ||
| Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT. | Q52990683 | ||
| Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer. | Q52990906 | ||
| 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer. | Q52997892 | ||
| The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology. | Q53009766 | ||
| Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients. | Q53023783 | ||
| Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. | Q53024450 | ||
| PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma. | Q53024527 | ||
| Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer. | Q53028164 | ||
| Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis? | Q53033729 | ||
| Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. | Q53043230 | ||
| Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. | Q53051809 | ||
| Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer. | Q53053248 | ||
| 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT. | Q53054241 | ||
| Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT. | Q53056812 | ||
| Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography. | Q53058794 | ||
| Need for standardization of 18F-FDG PET/CT for treatment response assessments | Q26998501 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K | Q30301096 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer | Q34987693 | ||
| FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. | Q35043725 | ||
| Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. | Q35095761 | ||
| PET scans as a predictive marker of survival in advanced colorectal cancer | Q35128437 | ||
| TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer | Q35155635 | ||
| Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast | Q35162694 | ||
| Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy | Q35178725 | ||
| Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study | Q35219168 | ||
| Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma | Q35232775 | ||
| Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer. | Q35242758 | ||
| The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication | Q35274923 | ||
| FDG PET/CT methodology for evaluation of treatment response in lymphoma: from "graded visual analysis" and "semiquantitative SUVmax" to global disease burden assessment. | Q53060839 | ||
| The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma. | Q53066807 | ||
| Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. | Q53293104 | ||
| Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. | Q53320501 | ||
| Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI. | Q53522480 | ||
| Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. | Q53533566 | ||
| Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study. | Q53652001 | ||
| Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. | Q54277397 | ||
| Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift! | Q54969527 | ||
| F-NaF and F-FDG as molecular probes in the evaluation of atherosclerosis | Q56342222 | ||
| Comparison of 18F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer | Q57998760 | ||
| Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study | Q60652342 | ||
| Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics | Q64230984 | ||
| Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT | Q85324460 | ||
| Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma | Q85737752 | ||
| Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results | Q85856939 | ||
| [18F]-FDG PET-CT prediction of response to induction chemotherapy in head and neck squamous cell carcinoma: preliminary findings | Q86090921 | ||
| The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy | Q86382333 | ||
| Guidelines for the first line management of classical Hodgkin lymphoma | Q87636826 | ||
| Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST? | Q87997472 | ||
| [18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma | Q88105492 | ||
| To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer | Q88288720 | ||
| FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial | Q91468639 | ||
| Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET? | Q91711465 | ||
| Personalized Clinical Decision Making in Gastrointestinal Malignancies: The Role of PET. | Q38870158 | ||
| 18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer | Q39006917 | ||
| Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors | Q39029324 | ||
| Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors | Q39030384 | ||
| The benefit of PET/CT in the diagnosis and treatment of esophageal cancer | Q39052638 | ||
| Evaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with (18)FDG-PET/CT. | Q39328635 | ||
| Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid t | Q40064495 | ||
| Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. | Q40219495 | ||
| Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings | Q40494935 | ||
| STatistically Assigned Response Criteria in Solid Tumors (STARCIST). | Q40672611 | ||
| Volumetric parameters changes of sequential 18F-FDG PET/CT for early prediction of recurrence and death in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy | Q40703948 | ||
| Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma | Q35439403 | ||
| A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer | Q35463464 | ||
| The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial | Q35475284 | ||
| Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. | Q35541792 | ||
| Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization | Q35570801 | ||
| Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT | Q35591793 | ||
| Longitudinal FDG-PET Revealed Regional Functional Heterogeneity of Bone Marrow, Site-Dependent Response to Treatment and Correlation with Hematological Parameters. | Q35631623 | ||
| Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT | Q35649202 | ||
| Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer | Q35677725 | ||
| Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. | Q35761121 | ||
| The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer | Q35793080 | ||
| Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings. | Q35840022 | ||
| Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography | Q35842799 | ||
| [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study | Q35855226 | ||
| FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up. | Q35929022 | ||
| Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr | Q35947019 | ||
| FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma | Q36023626 | ||
| Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer | Q36024114 | ||
| Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy. | Q36046360 | ||
| Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion | Q36086448 | ||
| Use of PET for monitoring cancer therapy and for predicting outcome | Q36152615 | ||
| Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery | Q36194573 | ||
| Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. | Q36214858 | ||
| Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235 | Q36288418 | ||
| Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma. | Q36295724 | ||
| Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer. | Q36322912 | ||
| 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients | Q36328330 | ||
| How to study optimal timing of PET/CT for monitoring of cancer treatment | Q36337232 | ||
| Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. | Q36355220 | ||
| Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study | Q36393691 | ||
| Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) | Q36417808 | ||
| Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer | Q36419166 | ||
| Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma | Q36432120 | ||
| Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT | Q36507013 | ||
| A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 | Q36533964 | ||
| 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer | Q36557319 | ||
| CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. | Q36706850 | ||
| Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | Q36734702 | ||
| Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators | Q36774004 | ||
| Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy | Q37149757 | ||
| Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review | Q37317418 | ||
| EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies | Q37433290 | ||
| Measuring response with FDG-PET: methodological aspects | Q37439095 | ||
| Assessing tumor response to therapy | Q37452321 | ||
| 3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer | Q37647591 | ||
| Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program | Q37861373 | ||
| 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. | Q38228115 | ||
| Assessment of treatment response using PET. | Q38279624 | ||
| PET-based radiation therapy planning. | Q38279625 | ||
| Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer | Q38286333 | ||
| The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). | Q38365591 | ||
| FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer | Q38367391 | ||
| Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma | Q38417140 | ||
| Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis. | Q38432601 | ||
| Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma | Q38435586 | ||
| Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype | Q38443820 | ||
| Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy | Q38510871 | ||
| [18F]Fluorodeoxyglucose PET in Thoracic Malignancies. | Q38518989 | ||
| Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma | Q38518999 | ||
| [18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy | Q38519006 | ||
| Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). | Q38543487 | ||
| Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. | Q38552173 | ||
| Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis | Q38641832 | ||
| Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer | Q38679329 | ||
| Using PET for therapy monitoring in oncological clinical trials: challenges ahead | Q38689940 | ||
| Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. | Q38747999 | ||
| Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using (68)Ga-PSMA-PET/CT. | Q38762861 | ||
| P433 | issue | 1 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 33-46 | |
| P577 | publication date | 2020-02-01 | |
| P1433 | published in | Molecular Imaging and Biology | Q6895951 |
| P1476 | title | PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues | |
| P478 | volume | 22 |
| Q92824847 | FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond |
| Q92648642 | Global disease score (GDS) is the name of the game! |
| Q90447700 | Mycobacterial Lymphadenitis in a Human Immunodeficiency Virus-Infected Patient: Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Diagnosis and Monitoring the Response to Treatment |
Search more.